This strategy has been extensively investigated in Huntington’s disease to improve the non-allele-specific huntingtin (HTT)-lowering gapmer ASO tominersen, of which a phase III trial was stopped due to worsening clinical outcomes.51 Here, HTT is linked to Huntington disease.